Similar articles for PMID: 14668794

Year	Number of Results
1992	1
1993	3
1995	1
1996	6
1997	10
1998	23
1999	25
2000	24
2001	26
2002	13
2003	18
2004	12
2005	22
2006	15
2007	6
2008	3
2009	3
2010	6
2011	4
2012	6
2013	4
2014	4
2015	7
2016	2
2017	9
2018	4
2019	1
2020	2
2021	5
2022	6
2023	4
2024	0

1

CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.

Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE, Geilen CC. Eberle J, et al. Oncogene. 2003 Dec 11;22(57):9131-41. doi: 10.1038/sj.onc.1207228. Oncogene. 2003. PMID: 14668794

2

Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk / Bik.

Oppermann M, Geilen CC, Fecker LF, Gillissen B, Daniel PT, Eberle J. Oppermann M, et al. Oncogene. 2005 Nov 10;24(49):7369-80. doi: 10.1038/sj.onc.1208890. Oncogene. 2005. PMID: 16007125

3

C2-ceramide signaling in glioma cells: synergistic enhancement of CD95-mediated, caspase-dependent apoptosis.

Wagenknecht B, Roth W, Gulbins E, Wolburg H, Weller M. Wagenknecht B, et al. Cell Death Differ. 2001 Jun;8(6):595-602. doi: 10.1038/sj.cdd.4400848. Cell Death Differ. 2001. PMID: 11536010

4

FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.

Imai T, Adachi S, Nishijo K, Ohgushi M, Okada M, Yasumi T, Watanabe K, Nishikomori R, Nakayama T, Yonehara S, Toguchida J, Nakahata T. Imai T, et al. Oncogene. 2003 Dec 18;22(58):9231-42. doi: 10.1038/sj.onc.1207184. Oncogene. 2003. PMID: 14647441

5

The regulation of CD95 ligand expression and function in CTL.

Li JH, Rosen D, Ronen D, Behrens CK, Krammer PH, Clark WR, Berke G. Li JH, et al. J Immunol. 1998 Oct 15;161(8):3943-9. J Immunol. 1998. PMID: 9780162

6

Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.

Ehl S, Hoffmann-Rohrer U, Nagata S, Hengartner H, Zinkernagel R. Ehl S, et al. J Immunol. 1996 Apr 1;156(7):2357-60. J Immunol. 1996. PMID: 8786290

7

Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.

Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR, Schön MP, Henkler F, Gollnick H, Walczak H, Leverkus M. Geserick P, et al. Oncogene. 2008 May 15;27(22):3211-20. doi: 10.1038/sj.onc.1210985. Epub 2007 Dec 17. Oncogene. 2008. PMID: 18084329

8

Apoptotic effects of mahanine on human leukemic cells are mediated through crosstalk between Apo-1/Fas signaling and the Bid protein and via mitochondrial pathways.

Bhattacharya K, Samanta SK, Tripathi R, Mallick A, Chandra S, Pal BC, Shaha C, Mandal C. Bhattacharya K, et al. Biochem Pharmacol. 2010 Feb 1;79(3):361-72. doi: 10.1016/j.bcp.2009.09.007. Epub 2009 Sep 12. Biochem Pharmacol. 2010. PMID: 19751707

9

CD95 ligand expression in dedifferentiated breast cancer.

Müschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann MW, Häussinger D. Müschen M, et al. J Pathol. 1999 Nov;189(3):378-86. doi: 10.1002/(SICI)1096-9896(199911)189:3<378::AID-PATH439>3.0.CO;2-D. J Pathol. 1999. PMID: 10547600

10

T cell activation-induced and HIV tat-enhanced CD95(APO-1/Fas) ligand transcription involves NF-kappaB.

Li-Weber M, Laur O, Dern K, Krammer PH. Li-Weber M, et al. Eur J Immunol. 2000 Feb;30(2):661-70. doi: 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.0.CO;2-L. Eur J Immunol. 2000. PMID: 10671224 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

264 results

Results by year